Please assess the completion status of the following clinical trial:

Trial Title: Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant women, aged 18-40 years~2. 18.5 kg/m2 \< pre-pregnancy BMI \< 27.5 kg/m2 \[representing low to moderate risk category, adapted from WHO expert panel recommendation on BMI categories for determining public health and clinical action (REF: Lancet, 2004)\]~3. Singleton pregnancy~4. Newly GDM diagnosed women between 24 to (the latest) 32 weeks of gestation;~5. Diagnosed GDM according to either:~   * World Health Organization (WHO) criteria if one or more glucose values equal to or exceed these threshold values \[75g Oral Glucose Tolerance Test: fasting 126 mg/dl; 2-h 140 mg/dl\] or~  * American Diabetic Association (ADA) criteria if two or more glucose values equal to or exceed these threshold values \[100g Oral Glucose Tolerance Test: fasting 95 mg/dl; 1-h 180 mg/dl; 2-h 155 mg/dl, 3-h 140/dl\]~6. Willing and able to comply with the protocol~7. Signed informed consent~Exclusion Criteria:~1. Any gastrointestinal disease that interferes with bowel function and nutritional intake (i.e. constipation or diarrhea secondary to neuropathy, diarrhea due to chronic inflammatory bowel disease, gastroparesis, gastrectomy, galactosaemia, hyperemesis)~2. Currently on anti-diabetic therapy, for example on insulin or oral anti-diabetic medication~3. Already using a diabetes nutritional/dietary supplement (e.g. Glucerna®, Nutrient Diabetes®) within 4 weeks prior to signing informed consent~4. Known allergy or intolerance for any of the following ingredients; fish, milk, protein, lactose, fiber or soy~5. Any significant medical condition, other than GDM, that might interfere with the study or known to affect intra-uterine growth (e.g. Type 1 Diabetes, Type 2 Diabetes Mellitus, Crohn's disease, HIV/AIDS, liver disease, kidney disease etc.)~6. Currently or previously on special low/no carbohydrate diet (e.g. Atkin's diet) within 8 weeks prior to signing informed consent~7. Incapability to comply with study protocol or Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements~8. Participation in other studies involving investigational or marketed products concomitantly or within 4 weeks prior signing informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Type: ACTIVE_COMPARATOR): Nutritional product as breakfast.
- Control Group (Type: OTHER): Standard breakfast according to ADA recommendations for pregnant women diagnosed with Gestational Diabetes Mellitus.

Based on this trial design, predict the completion outcome and termination type (if applicable).